Terms: = Kidney tumors AND RPL22, EAP, 6146
11 results:
1. Validation of the Meet-URO score in patients with metastatic renal cell carcinoma receiving first-line nivolumab and ipilimumab in the Italian Expanded Access Program.
Rebuzzi SE; Signori A; Buti S; Banna GL; Murianni V; Damassi A; Maruzzo M; Giannarelli D; Tortora G; Galli L; Rizzo M; De Giorgi U; Antonuzzo L; Bracarda S; Cartenì G; Atzori F; Tamberi S; Procopio G; Fratino L; Lo Re G; Santoni M; Baldessari C; Astone A; Calabrò F; Brunelli M; Porta C; Rescigno P; Basso U; Fornarini G
ESMO Open; 2022 Dec; 7(6):100634. PubMed ID: 36493602
[TBL] [Abstract] [Full Text] [Related]
2. Atezolizumab in patients with renal insufficiency and mixed variant histology: analyses from an expanded access program in platinum-treated locally advanced or metastatic urothelial carcinoma.
Hoffman-Censits J; Pal S; Kaiser C; Ding B; Bellmunt J
J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32641319
[TBL] [Abstract] [Full Text] [Related]
3. Efficacy and safety data in elderly patients with metastatic renal cell carcinoma included in the nivolumab Expanded Access Program (eap) in Italy.
Vitale MG; Scagliarini S; Galli L; Pignata S; Lo Re G; Berruti A; Defferrari C; Spada M; Masini C; Santini D; Ciuffreda L; Ruggeri EM; Bengala C; Livi L; Fagnani D; Bonetti A; Giustini L; Hamzaj A; Procopio G; Caserta C; Sabbatini R
PLoS One; 2018; 13(7):e0199642. PubMed ID: 29979712
[TBL] [Abstract] [Full Text] [Related]
4. Negative prognostic factors and resulting clinical outcome in patients with metastatic renal cell carcinoma included in the Italian nivolumab-expanded access program.
Bracarda S; Galli L; Maruzzo M; Lo Re G; Buti S; Favaretto A; Di Costanzo F; Sacco C; Merlano M; Mucciarini C; Zafarana E; Romito S; Maestri A; Giorgio CG; Ionta MT; Turci D; De Giorgi U; Procopio G; Cortesi E; Giannarelli D; Porta C
Future Oncol; 2018 Jun; 14(14):1347-1354. PubMed ID: 29774766
[TBL] [Abstract] [Full Text] [Related]
5. Lack of Cumulative Toxicity Associated With Cabazitaxel Use in Prostate Cancer.
Di Lorenzo G; Bracarda S; Gasparro D; Gernone A; Messina C; Zagonel V; Puglia L; Bosso D; Dondi D; Sonpavde G; Lucarelli G; De Placido S; Buonerba C
Medicine (Baltimore); 2016 Jan; 95(2):e2299. PubMed ID: 26765406
[TBL] [Abstract] [Full Text] [Related]
6. Safety and efficacy of sunitinib in patients from Italy with metastatic renal cell carcinoma: final results from an expanded-access trial.
Sternberg CN; Calabrò F; Bracarda S; Cartenì G; Lo Re G; Ruggeri EM; Basso U; Gasparini G; Ciuffreda L; Ferrari V; Bonetti A; Fea E; Gasparro D; Tassinari D; Labianca R; Masini C; Fly K; Zhang K; Hariharan S; Capaccetti B; Porta C
Oncology; 2015; 88(5):273-80. PubMed ID: 25592399
[TBL] [Abstract] [Full Text] [Related]
7. Laparoscopic management of renal hilar pheochromocytomas.
Bhandarkar D; Katara A; Mittal G; Chauhan P; Chadha M
Surg Laparosc Endosc Percutan Tech; 2012 Jun; 22(3):e148-51. PubMed ID: 22678338
[TBL] [Abstract] [Full Text] [Related]
8. Sunitinib in metastatic renal cell carcinoma patients with brain metastases.
Gore ME; Hariharan S; Porta C; Bracarda S; Hawkins R; Bjarnason GA; Oudard S; Lee SH; Carteni G; Nieto A; Yuan J; Szczylik C
Cancer; 2011 Feb; 117(3):501-9. PubMed ID: 20862748
[TBL] [Abstract] [Full Text] [Related]
9. Fine needle aspiration cytology of adrenocortical carcinoma--case report.
Misić M; Vidas Z; Skegro D; Kocman B; Jelić-Puskarić B; Kardum-Skelin I
Coll Antropol; 2010 Jun; 34(2):665-9. PubMed ID: 20698150
[TBL] [Abstract] [Full Text] [Related]
10. New developments in the treatment of gastric carcinoma.
Wilke H; Preusser P; Fink U; Achterrath W; Meyer HJ; Stahl M; Lenaz L; Meyer J; Siewert JR; Geerlings H
Semin Oncol; 1990 Feb; 17(1 Suppl 2):61-70. PubMed ID: 2305269
[TBL] [Abstract] [Full Text] [Related]
11. Extra-adrenal phaeochromocytoma. A case report.
Botma JP; de Kock ML
S Afr Med J; 1986 Jan; 69(2):143-4. PubMed ID: 3941952
[TBL] [Abstract] [Full Text] [Related]
